Implant Contraception

ABSTRACT

The experience of 6 million Norplant users has led to several more advanced implants. Implanon is a single-rod implant system containing a low androgenic progestin and requires 1 to 2 minutes for insertion and removal. Like other implants, Implanon prevents pregnancy by changing the character of the cervical mucus and interfering with luteal function. Unlike Norplant, though, Implanon is designed to prevent ovulation for the full duration of use. Implant contraception has several advantages over other types of contraception including high efficacy, minimal required maintenance, absence of estrogen, and rapid return of fertility after discontinuation. Implants can be a good choice for adolescents; women with hypertension, diabetes, anemia, endometriosis, or other medical problems; and women who are breast-feeding. Irregular bleeding is the most common adverse effect of implants and can be treated with several medication regimens. Preinsertion counseling, however, is the most important factor in ensuring satisfaction with implants. Unfortunately, no implant system is currently available in the United States since August 2000, but Implanon is expected to reach the U.S. market within the next 2 years.

KEYWORD

Implant - contraception - progestin-only - Implanon - Norplant

REFERENCES

• 1 Sivin I, Mishell Jr R D, Diaz S. Prolonged effectiveness of Norplant(R) capsule implants: a 7-year study.  Contraception . 2000;  61 187-194
• 2 Gu S, Sivin I, Du M. Effectiveness of Norplant implants through seven years: a large-scale study in China.  Contraception . 1995;  52 99-103
• 3 Du M K, Chow L P, Zheng H M, Chen C H. A 10-year follow-up study of contraceptive Norplant implants.  Int J Gynaecol Obstet . 2000;  68 249-256
• 4 Sivin I, Lahteenmaki P, Ranta S. Levonorgestrel concentrations during use of levonorgestrel rod (LNG ROD) implants.  Contraception . 1997;  55 81-85
• 5 Sivin I, Robertson D N, Stern J. Norplant: reversible implant contraception.  Stud Fam Plann . 1980;  11 227-235
• 6 Sivin I, Stern J, Diaz S. Rates and outcomes of planned pregnancy after use of Norplant capsules, Norplant II rods, or levonorgestrel-releasing or copper TCu 380Ag intrauterine contraceptive devices.  Am J Obstet Gynecol . 1992;  166 1208-1213
• 7 Gu S, Du M, Zhang L, Liu Y, Wang S, Sivin I. A five-year evaluation of Norplant II implants in China.  Contraception . 1994;  50 27-34
• 8 Singh K, Viegas O A, Ratnam S S. Acceptability of Norplant-2 rods as a method of family planning.  Contraception . 1992;  45 453-461
• 9 Sivin I, Alvarez F, Mishell Jr R D. Contraception with two levonorgestrel rod implants: a 5-year study in the United States and Dominican Republic.  Contraception . 1998;  58 275-282
• 10 Sivin I, Campodonico I, Kiriwat O. The performance of levonorgestrel rod and Norplant contraceptive implants: a 5 year randomized study.  Hum Reprod . 1998;  13 3371-3378
• 11 Darney P. The androgenicity of progestins.  Am J Medicine . 1995 (suppl 1A);  98 (104S-10S)
• 12 Bennink H J. The pharmacokinetics and pharmacodynamics of Implanon, a single-rod etonogestrel contraceptive implant.  Eur J Contracept Reprod Health Care . 2000 (suppl 2);  5 (12-20)
• 13 Wenzl R, van Beek A, Schnabel P, Huber J. Pharmacokinetics of etonogestrel released from the contraceptive implant Implanon.  Contraception . 1998;  58 283-288
• 14 Mascarenhas L. Insertion and removal of Implanon.  Contraception . 1998;  58(suppl) 79S-83S
• 15 Makarainen L, van Beek A, Tuomivaara L, Asplund B, Coelingh Bennink H. Ovarian function during the use of a single contraceptive implant: Implanon compared with Norplant.  Fertil Steril . 1998;  69 714-721
• 16 Zheng S R, Zheng H M, Qian S Z, Sang G W, Kaper R F. A long-term study of the efficacy and acceptability of a single-rod hormonal contraceptive implant (Implanon) in healthy women in China.  Eur J Contracept Reprod Health Care . 1999;  4 85-93
• 17 Herjan J T, Bennink. Introduction: presentation of clinical data on Implanon.  Contraception . 1998;  58 75S-77S
• 18 Diaz S, Schiappacasse V, Pavez M. Clinical trial with Nestorone subdermal contraceptive implants.  Contraception . 1995;  51 33-38
• 19 Haukkamaa M, Laurikka-Routti M, Heikinheimo O, Moo-Young A. Contraception with subdermal implants releasing the progestin ST-1435: a dose-finding study.  Contraception . 1992;  45 49-55
• 20 Heikinheimo O, Ranta S, Moo-Young A, Lahteenmaki P, Gordon K. Parenteral administration of progestin Nestorone to lactating cynomolgus monkeys: an ideal hormonal contraceptive at lactation?.  Hum Reprod . 1999;  14 1993-1997
• 21 Lahteenmaki P L, Diaz S, Miranda P, Croxatto H, Lahteenmaki P. Milk and plasma concentrations of the progestin ST-1435 in women treated parenterally with ST-1435.  Contraception . 1990;  42 555-562
• 22 Brache V, Massai R, Mishell D R. Ovarian function during use of Nestorone(R) subdermal implants.  Contraception . 2000;  61 199-204
• 23 Coutinho E, de Souza J, Athayde C. Multicenter clinical trial on the efficacy and acceptability of a single contraceptive implant of nomegestrol acetate, Uniplant.  Contraception . 1996;  53 121-125
• 24 Peralta O, Diaz S, Croxatto H. Subdermal contraceptive implants.  J Steroid Biochem Mol Biol . 1995;  53 223-226
• 25 Coutinho E M. One year contraception with a single subdermal implant containing nomegestrol acetate (Uniplant).  Contraception . 1993;  47 97-105
• 26 Croxatto H B. Progestin implants.  Steroids . 2000;  65 681-685
• 27 Darney P D, Klaisle C M, Monroe S E, Cook C E, Phillips N R, Schindler A. Evaluation of a 1-year levonorgestrel-releasing contraceptive implant: side effects, release rates, and biodegradability.  Fertil Steril . 1992;  58 137-143
• 28 Singh M, Saxena B B, Raghubanshi R S, Ledger W J, Harman S M, Leonard R J. Biodegradable norethindrone (NET:cholesterol) contraceptive implants, phase II-A: a clinical study in women.  Contraception . 1997;  55 23-33
• 29 Coukell A J, Balfour J A. Levonorgestrel subdermal implants: a review of contraceptive efficacy and acceptability.  Drugs . 1998;  55 861-887
• 30 Hatcher R A. Depo-Provera, Norplant, and progestin-only pills (minipills). In: Hatcher RA, Trussell J, Stewart F, et al, eds. Contraceptive Technology 17th ed. Cooper Station, NY: Ardent Media, Inc. 1998: 467-510
• 31 Faundes A, Brache V, Tejada A S, Cochon L, Alvarez-Sanchez F. Ovulatory dysfunction during continuous administration of low-dose levonorgestrel by subdermal implants.  Fertil Steril . 1991;  56 27-31
• 32 Croxatto H B, Makarainen L. The pharmacodynamics and efficacy of Implanon: an overview of the data.  Contraception . 1998;  58(suppl) 91S-97S
• 33 Sivin I. Contraception with Norplant implants.  Hum Reprod . 1994;  9 1818-1826
• 34 Alvarez F, Brache V, Faundes A, Tejada A S, Thevenin F. Ultrasonographic and endocrine evaluation of ovarian function among Norplant implants users with regular menses.  Contraception . 1996;  54 275-279
• 35 Brache V, Alvarez-Sanchez F, Faundes A, Tejada A S, Cochon L. Ovarian endocrine function through five years of continuous treatment with NORPLANT subdermal contraceptive implants.  Contraception . 1990;  41 169-177
• 36 Rice C F, Killick S R, Dieben T, Coelingh Bennink H. A comparison of the inhibition of ovulation achieved by desogestrel 75 micrograms and levonorgestrel 30 micrograms daily.  Hum Reprod . 1999;  14 982-985
• 37 Brache V, Faundes A, Johansson E, Alvarez F. Anovulation, inadequate luteal phase and poor sperm penetration in cervical mucus during prolonged use of Norplant implants.  Contraception . 1985;  31 261-273
• 38 Croxatto H B, Diaz S, Salvatierra A M, Morales P, Ebensperger C, Brandeis A. Treatment with Norplant subdermal implants inhibits sperm penetration through cervical mucus in vitro.  Contraception . 1987;  36 193-201
• 39 Dunson T R, Blumenthal P D, Alvarez F. Timing of onset of contraceptive effectiveness in Norplant implant users-part I: changes in cervical mucus.  Fertil Steril . 1998;  69 258-266
• 40 Barbosa I C, Coutinho E, Hirsch C, Ladipo O A, Olsson S E, Ulmsten U. Temporal relationship between Uniplant insertion and changes in cervical mucus.  Contraception . 1996;  54 213-217
• 41 Darney P D, Klaisle C M, Tanner S. Sustained release contraceptives.  Curr Probl Obstet Gynecol Fertil . 1990;  13 87-96
• 42 Trussell J, Hatcher R A, Cates Jr W, Stewart F H, Kost K. Contraceptive failure in the United States: an update.  Stud Fam Plann . 1990;  21 51-54
• 43 Sivin I, Mishell Jr R D, Darney P, Wan L, Christ M. Levonorgestrel capsule implants in the United States: a 5-year study.  Obstet Gynecol . 1998;  92 337-344
• 44 Sivin I. International experience with Norplant and Norplant-2 contraceptives.  Stud Fam Plann . 1988;  19 81-94
• 45 Diaz S, Pavez M, Miranda P, Robertson D N, Sivin I, Croxatto H B. A five-year clinical trial of levonorgestrel silastic implants (Norplant TM).  Contraception . 1982;  25 447-456
• 46 Huber J. Pharmacokinetics of Implanon: an integrated analysis.  Contraception . 1998;  58(suppl) 85S-90S
• 47 Grubb G S, Moore D, Anderson N G. Pre-introductory clinical trials of Norplant implants: a comparison of seventeen countries' experience.  Contraception . 1995;  52 287-296
• 48 Gu S J, Du M K, Zhang L D, Liu Y L, Wang S H, Sivin I. A 5-year evaluation of Norplant contraceptive implants in China.  Obstet Gynecol . 1994;  83 673-678
• 49 Olsson S E, Odlind V. ``Free levonorgestrel index'' (FLI) is a better parameter than plasma level of levonorgestrel for predicting risk of pregnancy during use of subdermal contraceptive implants releasing levonorgestrel.  Steroids . 1988;  52 407-408
• 50 Victor A, Johansson E D. Effects of d-norgestrel induced decreases in sex hormone binding globulin capacity on the d-norgestrel levels in plasma.  Contraception . 1977;  16 115-123
• 51 Affandi B, Cekan S Z, Boonkasemsanti W, Samil R S, Diczfalusy E. The interaction between sex hormone binding globulin and levonorgestrel released from Norplant, an implantable contraceptive.  Contraception . 1987;  35 135-145
• 52 Alvarez F, Brache V, Tejada A S, Cochon L, Faundes A. Sex hormone binding globulin and free levonorgestrel index in the first week after insertion of Norplant implants.  Contraception . 1998;  58 211-214
• 53 Barbosa I, Coutinho E, Athayde C, Ladipo O A, Olsson S E, Ulmsten U. Androgen levels in women using a single implant of nomegestrol acetate.  Contraception . 1996;  53 37-40
• 54 Franks A L, Beral V, Cates Jr W, Hogue C J. Contraception and ectopic pregnancy risk.  Am J Obstet Gynecol . 1990;  163 1120-1123
• 55 Moore D E, Roy S, Stanczyk F Z, Mishell Jr R D. Bleeding and serum d-norgestrel, estradiol and progesterone patterns in women using d-norgestrel subdermal polysiloxane capsules for contraception.  Contraception . 1978;  17 315-328
• 56 Brache V, Blumenthal P D, Alvarez F, Dunson T R, Cochon L, Faundes A. Timing of onset of contraceptive effectiveness in Norplant implant users II: effect on the ovarian function in the first cycle of use.  Contraception . 1999;  59 245-251
• 57 Croxatto H B, Diaz S, Pavez M, Caardenas H, Larsson M, Johansson E D. Clearance of levonorgestrel from the circulation following removal of Norplant subdermal implants.  Contraception . 1988;  38 509-523
• 58 Buckshee K, Chatterjee P, Dhall G I. Return of fertility following discontinuation of Norplant-II subdermal implants: ICMR Task Force on Hormonal Contraception.  Contraception . 1995;  51 237-242
• 59 Trussell J, Leveque J A, Koenig J D. The economic value of contraception: a comparison of 15 methods.  Am J Public Health . 1995;  85 494-503
• 60 Phillips C J. Economic analysis of long-term reversible contraceptives: focus on Implanon.  Pharmacoeconomics . 2000;  17 209-221
• 61 Croxatto H B, Diaz S, Robertson D N, Pavez M. Clinical chemistry in women treated with levonorgestrel implants (Norplant) or a TCu 200 IUD.  Contraception . 1983;  27 281-288
• 62 Konje J C, Otolorin E O, Ladipo O A. Changes in carbohydrate metabolism during 30 months on Norplant.  Contraception . 1991;  44 163-172
• 63 Koopersmith T B, Lobo R A. Insulin sensitivity is unaltered by the use of the Norplant subdermal implant contraceptive.  Contraception . 1995;  51 197-200
• 64 Barbosa I, Coutinho E, Athayde C, Ladipo O, Olsson S E, Ulmsten U. The effects of nomegestrol acetate subdermal implant (Uniplant) on carbohydrate metabolism, serum lipoproteins and on hepatic function in women.  Contraception . 1995;  52 111-114
• 65 Shaaban M M, Elwan S I, el-Sharkawy M M, Farghaly A S. Effect of subdermal levonorgestrel contraceptive implants, Norplant, on liver functions.  Contraception . 1984;  30 407-412
• 66 Singh K, Viegas O A, Koh S, Singh P, Ratnam S S. Two-year follow-up of changes in clinical chemistry in Singaporean Norplant-2 rod acceptors: haemostatic changes.  Contraception . 1989;  39 155-164
• 67 Singh K, Viegas O A, Koh S C, Ratnam S S. Effect of long-term use of Norplant implants on haemostatic function.  Contraception . 1992;  45 203-219
• 68 Viegas O A, Koh S C, Ratnam S S. The effects of reformulated 2-rod Norplant implant on hemostasis after three years.  Contraception . 1996;  54 219-228
• 69 Olsson S E. Contraception with subdermal implants releasing levonorgestrel: a clinical and pharmacological study.  Acta Obstet Gynecol Scand . 1987;  142(suppl) 1-45
• 70 Olsson S E, Wide L, Odlind V. Aspects of thyroid function during use of Norplant implants.  Contraception . 1986;  34 583-587
• 71 Anonymous. Data on file, Leiras Oy, Finland from Jadelle product monograph.  Chester, England: Adis International Limited for Leiras Oy, Finland 1998: 15
• 72 Biswas A, Viegas O A, Bennink H J, Korver T, Ratnam S S. Effect of Implanon use on selected parameters of thyroid and adrenal function.  Contraception . 2000;  62 247-251
• 73 Bayad M, Ibrahim I, Fayad M. Serum cortisol in women users of subdermal levonorgestrel implants.  Contracept Delivery Syst . 1983;  4 133
• 74 Olsson S E, Odlind V, Hammond G L. Plasma levels of cortisol and corticosteroid binding globulin during use of Norplant-2 implants.  Contraception . 1987;  35 353-361
• 75 Egberg N, van Beek A, Gunnervik C. Effects on the hemostatic system and liver function in relation to Implanon and Norplant: a prospective randomized clinical trial.  Contraception . 1998;  58 93-98
• 76 Shaaban M M, Elwan S I, el-Kabsh M Y, Farghaly S A, Thabet N. Effect of levonorgestrel contraceptive implants, Norplant, on blood coagulation.  Contraception . 1984;  30 421-430
• 77 Abdulla K A, Elwan S I, Salem H S, Shaaban M M. Effect of early postpartum use of the contraceptive implants, NORPLANT, on the serum levels of immunoglobulins of the mothers and their breastfed infants.  Contraception . 1985;  32 261-266
• 78 Shamma F N, Rossi G, HajHassan L. The effect of Norplant on glucose metabolism under hyperglycemic hyperinsulinemic conditions.  Fertil Steril . 1995;  63 767-772
• 79 World Health Organization. Improving access to quality care in family planning: medical eligibility criteria for contraceptive use Geneva: World Health Organization; 1996
• 80 United Nations Development Programme/United Nations Population Fund/World Health Organization/World Bank. Special Programme of Research, Development and Research Training in Human Reproduction, Task Force on Long-Acting Systemic Agents for Fertility Regulation. Study of the effects of the implantable contraceptive Norplant on lipid and lipoprotein metabolism.  Contraception . 1999;  59 31-45
• 81 Singh K, Viegas O, Loke D. Effect of Norplant implants on liver, lipid and carbohydrate metabolism.  Contraception . 1992;  45 141-153
• 82 Otubu J A, Towobola O A, Aisien A O, Ogunkeye O O. Effects of Norplant contraceptive subdermal implants on serum lipids and lipoproteins.  Contraception . 1993;  47 149-159
• 83 Shaaban M M, Elwan S I, Abdalla S A, Darwish H A. Effect of subdermal levonorgestrel contraceptive implants, Norplant, on serum lipids.  Contraception . 1984;  30 413-419
• 84 Rabe T, Thuro H C, Goebel K, Borchardt C, Grunwald K, Runnebaum B. Lipid metabolism in Norplant-2 users-a two-year follow-up study: total cholesterol, triglycerides, lipoproteins and apolipoproteins.  Contraception . 1992;  45 21-37
• 85 Singh K, Viegas O A, Liew D, Singh P, Ratnam S S. Two-year follow-up of changes in clinical chemistry in Singaporean Norplant-2 rod acceptors: metabolic changes.  Contraception . 1989;  39 147-154
• 86 Roy S, Mishell Jr R D, Robertson D N, Krauss R M, Lacarra M, Duda M J. Long-term reversible contraception with levonorgestrel-releasing Silastic rods.  Am J Obstet Gynecol . 1984;  148 1006-1013
• 87 Polaneczky M, Slap G, Forke C, Rappaport A, Sondheimer S. The use of levonorgestrel implants (Norplant) for contraception in adolescent mothers.  N Engl J Med . 1994;  331 1201-1206
• 88 Ruminjo J K, Amatya R N, Dunson T R, Krueger S L, Chi I. Norplant implants acceptability and user satisfaction among women in two African countries.  Contraception . 1996;  53 101-107
• 89 Clarke L L, Schmitt K, Bono C A, Steele J, Miller M K. Norplant selection and satisfaction among low-income women.  Am J Public Health . 1998;  88 1175-1181
• 90 Darney P D, Atkinson E, Tanner S, MacPherson S, Hellerstein S, Alvarado A. Acceptance and perceptions of Norplant among users in San Francisco, USA.  Stud Fam Plann . 1990;  21 152-160
• 91 Davie J E, Walling M R, Mansour D J, Bromham D, Kishen M, Fowler P. Impact of patient counseling on acceptance of the levonorgestrel implant contraceptive in the United Kingdom.  Clin Ther . 1996;  18 150-159
• 92 Oloto E J, Bromham D R, Walling M. Treatment of menstrual and non-menstrual side effects of Norplant: recommendations of an expert group.  Br J Fam Plann . 1995 (suppl 1);  21 (3-5)
• 93 Fraser I S, Tiitinen A, Affandi B. Norplant consensus statement and background review.  Contraception . 1998;  57 1-9
• 94 Shoupe D, Mishell Jr R D, Bopp B L, Fielding M. The significance of bleeding patterns in Norplant implant users.  Obstet Gynecol . 1991;  77 256-260
• 95 Diaz J, Faundes A, Olmos P, Diaz M. Bleeding complaints during the first year of Norplant implants use and their impact on removal rate.  Contraception . 1996;  53 91-95
• 96 Coutinho E M, Athayde C, Barbosa I. Results of a user satisfaction study carried out in women using Uniplant contraceptive implant.  Contraception . 1996;  54 313-317
• 97 Vekemans M, Delvigne A, Paesmans M. Continuation rates with a levonorgestrel-releasing contraceptive implant (Norplant): a prospective study in Belgium.  Contraception . 1997;  56 291-299
• 98 Fleming D, Davie J, Glasier A. Continuation rates of long-acting methods of contraception: a comparative study of Norplant implants and intrauterine devices.  Contraception . 1998;  57 19-21
• 99 Frank M L, Ditmore J R, Ilegbodu A E, Bateman L, Poindexter III N A. Characteristics and experiences of American women electing for early removal of contraceptive implants.  Contraception . 1995;  52 159-165
• 100 Croxatto H B. Clinical profile of Implanon: a single-rod etonogestrel contraceptive implant.  Eur J Contracept Reprod Health Care . 2000 (suppl 2);  5 (21-28)
• 101 Polaneczky M. Adolescent contraception.  Curr Opin Obstet Gynecol . 1998;  10 213-219
• 102 Glantz S, Schaff E, Campbell-Heider N, Glantz J C, Bartlett M. Contraceptive implant use among inner city teens.  J Adolesc Health . 1995;  16 389-395
• 103 Darney P D, Callegari L S, Swift A, Atkinson E S, Robert A M. Condom practices of urban teens using Norplant contraceptive implants, oral contraceptives, and condoms for contraception.  Am J Obstet Gynecol . 1999;  180 929-937
• 104 Meirik O, Farley T M, Sivin I. Safety and efficacy of levonorgestrel implant, intrauterine device, and sterilization.  Obstet Gynecol . 2001;  97 539-547
• 105 Urbancsek J. An integrated analysis of nonmenstrual adverse events with Implanon.  Contraception . 1998;  58(suppl) 109S-115S
• 106 Zheng S R, Zheng H M, Qian S Z, Sang G W, Kaper R F. A randomized multicenter study comparing the efficacy and bleeding pattern of a single-rod (Implanon) and a six-capsule (Norplant) hormonal contraceptive implant.  Contraception . 1999;  60 1-8
• 107 Fraser I S, Weisberg E, Minehan E, Johansson E D. A detailed analysis of menstrual blood loss in women using Norplant and Nestorone progestogen-only contraceptive implants or vaginal rings.  Contraception . 2000;  61 241-251
• 108 Aisien A O, Sagay A S, Imade G E, Ujah I A, Nnana O U. Changes in menstrual and haematological indices among Norplant acceptors.  Contraception . 2000;  61 283-286
• 109 Datey S, Gaur L N, Saxena B N. Vaginal bleeding patterns of women using different contraceptive methods (implants, injectables, IUDs, oral pills)-an Indian experience: an ICMR Task Force Study. Indian Council of Medical Research.  Contraception . 1995;  51 155-165
• 110 Cromer B A, Smith R D, Blair J M, Dwyer J, Brown R T. A prospective study of adolescents who choose among levonorgestrel implant (Norplant), medroxyprogesterone acetate (Depo-Provera), or the combined oral contraceptive pill as contraception.  Pediatrics . 1994;  94 687-694
• 111 Diaz S, Pavez M, Herreros C, Johansson E D, Croxatto H B. Bleeding pattern, outcome of accidental pregnancies and levonorgestrel plasma levels associated with method failure in Norplant implants users.  Contraception . 1986;  33 347-356
• 112 Affandi B. An integrated analysis of vaginal bleeding patterns in clinical trials of Implanon.  Contraception . 1998;  58(suppl) 99S-107S
• 113 Chompootaweep S, Kochagarn E, Sirisumpan S, Tang-usaha J, Theppitaksak B, Dusitsin N. Effectiveness of Norplant implants among Thai women in Bangkok.  Contraception . 1996;  53 33-36
• 114 Dugoff L, Jones III W O, Allen-Davis J, Hurst B S, Schlaff W D. Assessing the acceptability of Norplant contraceptive in four patient populations.  Contraception . 1995;  52 45-49
• 115 Faundes A, Alvarez F, Brache V, Cochon L. Endometrial thickness and oestradiol concentration in women with bleeding complaints during use of Norplant implants.  Hum Reprod . 1998;  13 188-191
• 116 Faundes A, Alvarez-Sanchez F, Brache V, Jimenez E, Tejada A S. Hormonal changes associated with bleeding during low dose progestogen contraception delivered by Norplant subdermal implants.  Adv Contracept . 1991;  7 85-94
• 117 Darney P D, Taylor R N, Klaisle C, Bottles K, Zaloudek C. Serum concentrations of estradiol, progesterone, and levonorgestrel are not determinants of endometrial histology or abnormal bleeding in long-term Norplant implant users.  Contraception . 1996;  53 97-100
• 118 Kaewrudee S, Taneepanichskul S, Jaisamraun U, Reinprayoon D. The effect of mefenamic acid on controlling irregular uterine bleeding secondary to Norplant use.  Contraception . 1999;  60 25-30
• 119 Diaz S, Croxatto H B, Pavez M, Belhadj H, Stern J, Sivin I. Clinical assessment of treatments for prolonged bleeding in users of Norplant implants.  Contraception . 1990;  42 97-109
• 120 Archer D F, Philput C A, Weber M E. Management of irregular uterine bleeding and spotting associated with Norplant.  Hum Reprod . 1996;  11(suppl) 24-30
• 121 Witjaksono J, Lau T M, Affandi B, Rogers P A. Oestrogen treatment for increased bleeding in Norplant users: preliminary results.  Hum Reprod . 1996 (suppl 2);  11 (109-114)
• 122 Alvarez-Sanchez F, Brache V, Thevenin F, Cochon L, Faundes A. Hormonal treatment for bleeding irregularities in Norplant implant users.  Am J Obstet Gynecol . 1996;  174 919-922
• 123 Subakir S B, Setiadi E, Affandi B, Pringgoutomo S, Freisleben H J. Benefits of vitamin E supplementation to Norplant users: in vitro and in vivo studies.  Toxicology . 2000;  148 173-178
• 124 Cheng L, Zhu H, Wang A, Ren F, Chen J, Glasier A. Once a month administration of mifepristone improves bleeding patterns in women using subdermal contraceptive implants releasing levonorgestrel.  Hum Reprod . 2000;  15 1969-1972
• 125 Boonkasemsanti W, Reinprayoon D, Pruksananonda K. The effect of transdermal oestradiol on bleeding pattern, hormonal profiles and sex steroid receptor distribution in the endometrium of Norplant users.  Hum Reprod . 1996 (suppl 2);  11 (115-123)
• 126 Sivin I, Viegas O, Campodonico I. Clinical performance of a new two-rod levonorgestrel contraceptive implant: a three-year randomized study with Norplant implants as controls.  Contraception . 1997;  55 73-80
• 127 Berenson A B, Wiemann C M, Rickerr V I, McCombs S L. Contraceptive outcomes among adolescents prescribed Norplant implants versus oral contraceptives after one year of use.  Am J Obstet Gynecol . 1997;  176 586-592
• 128 Croxatto H B, Urbancsek J, Massai R, Coelingh Bennink H, van Beek A. A multicentre efficacy and safety study of the single contraceptive implant Implanon: Implanon Study Group.  Hum Reprod . 1999;  14 976-981
• 129 Alder J B, Fraunfelder F T, Edwards R. Levonorgestrel implants and intracranial hypertension [letter].  N Engl J Med . 1995;  332 1720-1721
• 130 Cundy T, Evans M, Roberts H, Wattie D, Ames R, Reid I R. Bone density in women receiving depot medroxyprogesterone acetate for contraception.  BMJ (Clinical Research Ed) . 1991;  303 13-16
• 131 Cromer B A. Effects of hormonal contraceptives on bone mineral density.  Drug Safety . 1999;  20 213-222
• 132 Cromer B A, Blair J M, Mahan J D, Zibners L, Naumovski Z. A prospective comparison of bone density in adolescent girls receiving depot medroxyprogesterone acetate (Depo-Provera), levonorgestrel (Norplant), or oral contraceptives.  J Pediatr . 1996;  129 671-676
• 133 Naessen T, Olsson S E, Gudmundson J. Differential effects on bone density of progestogen-only methods for contraception in premenopausal women.  Contraception . 1995;  52 35-39
• 134 Taneepanichskul S, Intaraprasert S, Theppisai U, Chaturachinda K. Bone mineral density during long-term treatment with Norplant implants and depot medroxyprogesterone acetate: a cross-sectional study of Thai women.  Contraception . 1997;  56 153-155
• 135 Diffey B, Piers L S, Soares M J, O'Dea K. The effect of oral contraceptive agents on the basal metabolic rate of young women.  Br J Nutr . 1997;  77 853-862
• 136 Wagner K D. Major depression and anxiety disorders associated with Norplant.  J Clin Psychiatry . 1996;  57 152-157
• 137 Berenson A B, Wiemann C M. Patient satisfaction and side effects with levonorgestrel implant (Norplant) use in adolescents 18 years of age or younger.  Pediatrics . 1993;  92 257-260
• 138 Westhoff C, Truman C, Kalmuss D. Depressive symptoms and Norplant contraceptive implants.  Contraception . 1998;  57 241-245
• 139 Klavon S L, Grubb G S. Insertion site complications during the first year of Norplant use.  Contraception . 1990;  41 27-37
• 140 Janowsky E C, Kupper L L, Hulka B S. Meta-analyses of the relation between silicone breast implants and the risk of connective-tissue diseases.  N Engl J Med . 2000;  342 781-790
• 141 Harrison P F, Rosenfield A. Research, introduction, and use: advancing from Norplant.  Contraception . 1998;  58 323-334
• 142 Wysowski D K, Green L. Serious adverse events in Norplant users reported to the Food and Drug Administration's MedWatch Spontaneous Reporting System.  Obstet Gynecol . 1995;  85 538-542
• 143 Hueston W J, Locke K T. Norplant neuropathy: peripheral neurologic symptoms associated with subdermal contraceptive implants.  J Fam Pract . 1995;  40 184-186
• 144 Brittain J, Lange L S. Myasthenia gravis and levonorgestrel implant [letter; comment].  Lancet . 1995;  346 1556
• 145 Gbolade B A. Post-Norplant implants insertion anaphylactoid reaction: a case report.  Contraception . 1997;  55 319-320
• 146 Roye C F. Condom use by Hispanic and African-American adolescent girls who use hormonal contraception.  J Adolesc Health . 1998;  23 205-211
• 147 Haukkamaa M. Contraception by Norplant subdermal capsules is not reliable in epileptic patients on anticonvulsant treatment.  Contraception . 1986;  33 559-565
• 148 Fattore C, Cipolla G, Gatti G. Induction of ethinylestradiol and levonorgestrel metabolism by oxcarbazepine in healthy women.  Epilepsia . 1999;  40 783-787
• 149 Shane-McWhorter L, Cerveny J D, MacFarlane L L, Osborn C. Enhanced metabolism of levonorgestrel during phenobarbital treatment and resultant pregnancy.  Pharmacotherapy . 1998;  18 1360-1364
• 150 Taneepanichskul S, Intaraprasert S, Phuapradit W, Chaturachinda K. Use of Norplant implants in asymptomatic HIV-1 infected women.  Contraception . 1997;  55 205-207
• 151 Ladipo O A, Falusi A G, Feldblum P J, Osotimehin B O, Otolorin E O, Ojengbede O A. Norplant use by women with sickle cell disease.  Int J Gynaecol Obstet . 1993;  41 85-87
• 152 United Nations Development Programme/United Nations Population Fund/World Health Organization/World Bank. Special Programme of Research, Development and Research Training in Human Reproduction, World Health Organization, Geneva, Switzerland, Task Force for Epidemiological Research on Reproductive Health. Effects of contraceptives on hemoglobin and ferritin.  Contraception . 1998;  58 262-273
• 153 Kennedy K I, Short R V, Tully M R. Premature introduction of progestin-only contraceptive methods during lactation.  Contraception . 1997;  55 347-350
• 154 Shikary Z K, Betrabet S S, Patel Z M. ICMR task force study on hormonal contraception: transfer of levonorgestrel (LNG) administered through different drug delivery systems from the maternal circulation into the newborn infant's circulation via breast milk.  Contraception . 1987;  35 477-486
• 155 Shaaban M M, Odlind V, Salem H T, Abdullah K A, Gomaa A A. Levonorgestrel concentrations in maternal and infant serum during use of subdermal levonorgestrel contraceptive implants, Norplant, by nursing mothers.  Contraception . 1986;  33 357-363
• 156 Diaz S, Zepeda A, Maturana X. Fertility regulation in nursing women IX: contraceptive performance, duration of lactation, infant growth, and bleeding patterns during use of progesterone vaginal rings, progestin-only pills, Norplant implants, and Copper T 380-A intrauterine devices.  Contraception . 1997;  56 223-232
• 157 World Health Organization Task Force for Epidemiological Research on Reproductive Health. Progestogen-only contraceptives during lactation I: infant growth.  Contraception . 1994;  50 35-55
• 158 World Health Organization Task Force for Epidemiological Research on Reproductive Health. Progestogen-only contraceptives during lactation II: infant development.  Contraception . 1994;  50 55-68
• 159 Shaaban M M, Salem H T, Abdullah K A. Influence of levonorgestrel contraceptive implants, Norplant, initiated early postpartum upon lactation and infant growth.  Contraception . 1985;  32 623-635
• 160 Abdel-Aleem H, Abol-Oyoun el M S, Shaaban M M. The use of nomegestrol acetate subdermal contraceptive implant, uniplant, during lactation.  Contraception . 1996;  54 281-286
• 161 Coutinho E M, Athayde C, Dantas C, Hirsch C, Barbosa I. Use of a single implant of elcometrine (ST-1435), a nonorally active progestin, as a long acting contraceptive for postpartum nursing women.  Contraception . 1999;  59 115-122
• 162 Cullins V E, Blumenthal P D, Remsburg R E, Huggins G R. Preliminary experience with Norplant in an inner city population.  Contraception . 1993;  47 193-203
• 163 Praptohardjo U, Wibowo S. The ``U'' technique: a new method for Norplant implants removal.  Contraception . 1993;  48 526-536
• 164 Darney P D, Klaisle C M, Walker D M. The pop-out method of Norplant removal.  Adv Contracept . 1992;  8 188-189
• 165 Sarma S P, Hatcher R. The Emory method: a modified approach to Norplant implants removal.  Contraception . 1994;  49 551-556
• 166 Shihata A A, Salzetti R G, Schnepper F W, Deutsch G. Innovative technique for Norplant implants removal.  Contraception . 1995;  51 83-85
• 167 Ward C R, Peterson C M, Hatasaka H H. A hook-traction technique for Norplant removal.  Obstet Gynecol . 1995;  86 848-850
• 168 Zieman M, Klaisle C, Walker D, Bailstrei E, Darney P D. Fingers versus instruments for removing levonorgestrel contraceptive implants (Norplant).  J Gynecol Tech . 1997;  3 213-217
• 169 Pymar H C, Creinin M D, Schwartz J L. ``Pop-out'' method of levonorgestrel implant removal.  Contraception . 1999;  59 383-387
• 170 Speroff L, Darney P D. A Clinical Guide for Contraception.  2nd ed. Baltimore: Williams & Wilkins; 1996
• 171 Klaisle C, Zieman M, Allen J, Patel M, Sickles E, Darney P. Insertion, removal and imaging of subdermal contraceptive capsules.  Am J Obstet Gynecol. ;